Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;161(3):660-667.
doi: 10.1016/j.ygyno.2021.04.012. Epub 2021 Apr 16.

Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer

Roni Nitecki  1 , Nicole D Fleming  1 , Bryan M Fellman  2 , Larissa A Meyer  1 , Anil K Sood  1 , Karen H Lu  1 , J Alejandro Rauh-Hain  3
Affiliations

Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer

Roni Nitecki et al. Gynecol Oncol. 2021 Jun.

Abstract

Objective: The ideal number of neoadjuvant chemotherapy (NACT) cycles prior to interval tumor-reductive surgery (iTRS) for advanced ovarian cancer is poorly defined. We sought to assess survival stratified by number of NACT cycles and residual disease following iTRS in patients with advanced ovarian cancer with partial response (PR) or stable disease (SD) following 3-4 cycles of NACT.

Methods: We retrospectively identified patients with advanced high-grade ovarian cancer (diagnosed 2/1/2013 to 2/1/2018) who received at least 3 cycles of NACT and iTRS and had a PR or SD. The population was divided into four groups based on the number of NACT cycles prior to iTRS and residual disease status after (CGR [complete gross residual] or incomplete resection [any amount of residual disease]): 1) 3-4 NACT cycles/CGR, 2) 3-4 NACT cycles/incomplete resection, 3) > 4 cycles/CGR, and 4) >4 cycles/incomplete resection. Overall survival (OS) and progression-free survival (PFS) were estimated using a Kaplan-Meier product-limit estimator and modeled using univariable and multivariable Cox proportional hazards analysis.

Results: The cohort consisted of 265 patients with advanced high-grade ovarian cancer with a median age at diagnosis of 65 years. Most were White (87%), had serous histology (89%), and stage IV disease (57%), with an overall CGR rate of 81%. In a multivariable analysis receipt of >4 NACT cycles was not associated with worse PFS or OS (adjusted hazard ratio [aHR] 1.02, 95% CI 0.74-1.42; aHR 1.12, 95% CI, 0.73-1.72 respectively) than was receipt of 3-4 cycles. Any amount of residual disease was associated with worse PFS and OS regardless of the number of NACT cycles (aHR 1.56, 95% CI 1.09-2.22; aHR 2.38, 95% CI 1.52-3.72 respectively).

Conclusions: Residual disease was associated with worse survival outcomes regardless of the number of NACT cycles in patients with PR or SD after NACT for advanced high-grade ovarian cancer. These data suggest that the ability to achieve CGR should take precedence in decision-making regarding the timing of surgery.

Keywords: Interval tumor reductive surgery; Neoadjuvant chemotherapy; Ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest R.N., K.H.L, and J.A.R-H have nothing to disclose. N.D·F reports personal fees from Tesaro, personal fees from BMS/Pfizer, personal fees from Glaxo Smith Kline, outside the submitted work; B.M.F. and L.A.M report grants from NIH, during the conduct of the study. A.K.S reports grants from NIH Grants during the conduct of the study as well as consulting fees from Merck and Kiyatec, shareholder position in Biopath, other from Kiyatec, and research funding from M-Trap, outside the submitted work.

Figures

Fig. 1.
Fig. 1.
CONSORT flow diagram of the cohort selection process used in this study.
Fig 2.
Fig 2.
2a. Kaplan-Meier curve of PFS by treatment group; 2b. Kaplan-Meier curve of OS by treatment group CGR, complete gross resection; IR, Incomplete resection
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. National Cancer Institute: Surveillance, epidemiology, and end results program. Cancer stat facts: ovarian cancer, (n.d.). https://seer.cancer.gov/statfacts/html/ovary.html (accessed January 25, 2021).
    1. Knisely AT, Clair CM St., Hou JY, Collado FK, Hershman DL, Wright JD, Melamed A, Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016, JAMA Netw. Open 3 (2020) e2017517. doi:10.1001/jamanetworkopen.2020.17517. - DOI - PMC - PubMed
    1. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RHM, van der Burg MEL, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GCE, Pecorelli S, Reed NS, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer., N. Engl. J. Med 363 (2010) 943–953. doi:10.1056/NEJMoa0908806. - DOI - PubMed
    1. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart A-M, Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, Lancet. 386 (2015) 249–257. doi:10.1016/S0140-6736(14)62223-6. - DOI - PubMed
    1. Onda T, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T, Mizutani T, Takehara K, Okamoto A, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Kanao H, Watanabe Y, Yamamoto K, Yaegashi N, Kamura T, Yoshikawa H, Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial, Eur. J. Cancer 130 (2020) 114–125. doi:10.1016/j.ejca.2020.02.020. - DOI - PubMed

Publication types